What Is GLP-1 Medication? A Physician's Guide to the Weight Loss and Diabetes Drugs Changing Medicine

What Is GLP-1 Medication? A Physician's Guide to the Weight Loss and Diabetes Drugs Changing Medicine

By Dr. Onikepe Adegbola, MD PhD

GLP-1 medication refers to a class of prescription drugs called GLP-1 receptor agonists that mimic a natural gut hormone to lower blood sugar, reduce appetite, and promote weight loss. You've seen the brand names: Ozempic, Wegovy, Mounjaro, Zepbound. These medications have become the most significant advancement in obesity treatment in decades, and their applications keep expanding.

As a physician prescribing GLP-1 medication daily at Mochi Health, I watch patients transform their metabolic health in ways that diet and exercise alone couldn't achieve. But I also see confusion, misinformation, and unrealistic expectations. This guide covers what GLP-1 medications actually are, how they work, who they're for, and what the experience of taking them looks like in reality.

Key Takeaways

• GLP-1 medications work by mimicking the incretin hormone GLP-1, which regulates insulin, appetite, and gastric emptying
• FDA-approved GLP-1 medications include semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and liraglutide (Saxenda)
• Average weight loss ranges from 15-22% of body weight depending on the specific medication
• Common side effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation
• These medications require ongoing use; weight regain after discontinuation is common without sustained lifestyle changes

The GLP-1 Medications Currently Available

The GLP-1 medication market has expanded rapidly. Here's what's currently FDA-approved and how each option differs.

Semaglutide

Ozempic (0.25 mg, 0.5 mg, 1 mg, 2 mg weekly injection): Approved for type 2 diabetes. Widely used off-label for weight management before Wegovy became available. This was the medication that launched the GLP-1 cultural phenomenon.

Wegovy (0.25 mg titrating to 2.4 mg weekly injection): Approved specifically for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition. The higher maintenance dose produces greater weight loss than Ozempic's 2 mg maximum.

Rybelsus (3 mg, 7 mg, 14 mg daily oral tablet): The first oral GLP-1 receptor agonist. Approved for type 2 diabetes. Lower bioavailability than injectable semaglutide means lower efficacy for weight loss, but eliminates the need for injections.

Tirzepatide

Mounjaro (2.5 mg titrating to 15 mg weekly injection): Approved for type 2 diabetes. A dual GIP/GLP-1 receptor agonist that activates two incretin pathways simultaneously.

Zepbound (2.5 mg titrating to 15 mg weekly injection): The obesity-specific indication for tirzepatide. Same molecule as Mounjaro, different label. The SURMOUNT trials showed average weight loss of 20-22% of body weight.

Liraglutide

Saxenda (0.6 mg titrating to 3 mg daily injection): The first GLP-1 receptor agonist approved for weight management. Average weight loss is more modest (approximately 8% of body weight) compared to newer options. Daily injection frequency is less convenient than weekly alternatives.

Other GLP-1 Receptor Agonists

Dulaglutide (Trulicity) and exenatide (Byetta, Bydureon) are approved for type 2 diabetes but are not commonly used primarily for weight management. Their weight loss effects are generally less pronounced than semaglutide or tirzepatide.

What GLP-1 Medication Actually Does in Your Body

When patients ask me what is GLP-1 medication doing inside them, I break it down into four parallel effects:

Appetite reduction through brain signaling. GLP-1 receptors in the hypothalamus and brainstem receive signals that reduce hunger, decrease food reward activation, and promote satiety. Patients describe this as "food noise going quiet." The constant background hum of thinking about food, craving, and planning meals drops to a whisper. This isn't willpower. It's altered neurochemistry.

Slowed gastric emptying. Food moves from the stomach to the small intestine more slowly. This reduces post-meal glucose spikes and extends the physical sensation of fullness after eating. It's also the primary driver of nausea, the most common side effect.

Enhanced insulin secretion (glucose-dependent). When blood sugar rises after a meal, GLP-1 medication amplifies the pancreas's insulin response. Because this is glucose-dependent, the risk of dangerously low blood sugar is lower than with older diabetes medications.

Glucagon suppression. The liver stores glucose and releases it between meals. GLP-1 medication reduces inappropriate glucagon signaling that causes the liver to release glucose when levels are already adequate.

These four effects together create a metabolic environment where patients eat less, absorb food more gradually, manage blood sugar more tightly, and lose weight. The degree of each effect varies between medications, doses, and individuals.

The Real-World Experience of Taking GLP-1 Medication

Clinical trial results represent averages across large populations. Individual experience varies. Here's what I consistently observe in practice.

The First Four Weeks

Most patients begin with the lowest dose and titrate upward. The first weeks are adjustment. Nausea is common but usually mild at starting doses. Appetite changes begin immediately in some patients and take 2-3 weeks in others. Weight loss in the first month is often 3-6 pounds, a mix of water loss and early fat loss.

I tell patients: don't judge the medication by the first month. The dose you start on is not the dose that produces the clinical effect. It's designed to let your GI system adapt.

Months Two Through Six

This is where the trajectory becomes clear. As doses escalate, appetite suppression strengthens and weight loss accelerates. Patients typically lose 1-2 pounds per week during this phase. GI side effects may recur with each dose increase and then settle.

This is also when nutritional challenges emerge. Eating less means getting fewer vitamins, minerals, and protein unless patients are intentional about food choices. Muscle preservation requires adequate protein intake (0.7-1.0 g per pound of lean body mass). Many patients don't hit that target without supplementation.

Six Months and Beyond

Weight loss typically plateaus between 9-15 months. At maintenance, the medication continues working on appetite and metabolism, but the body has recalibrated to a new lower weight. Some patients reach their goal. Others plateau above it. Both outcomes are clinically successful if metabolic health markers have improved.

The maintenance phase requires continued medication for most patients. Studies show that two-thirds of weight lost is regained within a year of discontinuation. This isn't failure. It reflects the chronic nature of obesity as a metabolic disease. We don't stop blood pressure medications when blood pressure normalizes. The same logic applies here.

Managing Side Effects and Nutritional Needs

The most common side effects of GLP-1 medication are gastrointestinal: nausea (40-44%), diarrhea (29-30%), vomiting (24%), and constipation (24%). These figures come from clinical trials at therapeutic doses. Most side effects improve with time as the body adapts.

Management strategies that work in my clinical practice:

• Eat smaller, more frequent meals rather than two or three large ones
• Avoid high-fat and heavily spiced foods during dose escalation
• Stay hydrated with small, frequent sips rather than large volumes at once
• Don't eat past the point of comfortable fullness. The delayed gastric emptying means the sensation of "too full" can escalate into nausea quickly
• Protein first, then vegetables, then starches at each meal. This prioritizes the nutrient you need most

Supplementation during GLP-1 therapy addresses the gap between reduced intake and unchanged nutritional requirements. Casa de Sante GLP-1 supplements offer a targeted approach: digestive enzymes for the altered GI motility, protein supplements for muscle preservation, and vitamin-mineral complexes for micronutrient gaps. These formulations are low-FODMAP and gut-gentle, designed for digestive systems that are already dealing with medication-related changes.

Who Is a Candidate for GLP-1 Medication?

FDA-approved indications for weight management (Wegovy, Zepbound) include:

• Adults with BMI ≥30 (obesity)
• Adults with BMI ≥27 (overweight) plus at least one weight-related condition such as type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea

For diabetes-specific indications (Ozempic, Mounjaro), the criteria are type 2 diabetes inadequately controlled with current therapy.

Who should not take GLP-1 medication:

• Patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
• Patients with a history of pancreatitis (relative contraindication; requires risk-benefit discussion)
• Pregnant or breastfeeding women
• Patients with severe gastroparesis

The decision to start GLP-1 medication should involve a thorough evaluation by a qualified physician, including medical history, current medications, metabolic labs, and a realistic discussion of expectations.

Frequently Asked Questions

What is GLP-1 medication used for?

GLP-1 medication is FDA-approved for two primary indications: type 2 diabetes management and chronic weight management (obesity). Research is exploring additional applications including cardiovascular risk reduction (already approved for semaglutide), fatty liver disease, chronic kidney disease, and potentially neurodegenerative conditions. Your prescriber determines whether GLP-1 medication is appropriate for your specific clinical situation.

How long do you stay on GLP-1 medication?

Current evidence supports long-term use for most patients. Obesity is a chronic condition, and GLP-1 medications treat the underlying metabolic dysfunction. Studies show significant weight regain after discontinuation. Some patients eventually transition to lower maintenance doses. Others maintain their therapeutic dose indefinitely. This is an ongoing conversation between you and your physician based on your individual response and health goals.

Are GLP-1 medications safe long-term?

Semaglutide has been on the market since 2017 (Ozempic) with extensive post-marketing surveillance. Clinical trials have followed patients for up to two years. The cardiovascular safety data is actually favorable (20% reduction in MACE events). The most common long-term concerns are gallbladder disease, potential pancreatic effects, and the ongoing GI side effects that affect some patients. Your physician monitors for these with periodic lab work and symptom assessment.

What is the strongest GLP-1 medication for weight loss?

Based on current clinical trial data, tirzepatide (Zepbound) at maximum dose produces the highest average weight loss at approximately 20-22% of body weight. Semaglutide 2.4 mg (Wegovy) produces average weight loss of 15-17%. Individual responses vary considerably. Some patients respond better to semaglutide than tirzepatide and vice versa. "Strongest" also isn't always the right framework; the best medication is the one that produces meaningful results with tolerable side effects for you specifically.